The EWOR Ideation Fellowship funds exceptional early-stage founders building generational-impact ventures, particularly those applying frontier technologies (e.g., AI, biophysics) to solve hard problems. It exists to identify and support outlier talent globally, providing capital and mentorship before traditional accelerators, with a thesis that transformative companies come from unconventional backgrounds.

- Founder exceptionalism: demonstrated grit, domain expertise, and a track record of overcoming obstacles (e.g., pharmacist-turned-ML engineer, solo founder from Nigeria). - Venture impact potential: technology that addresses a massive, unsolved problem (e.g., predicting drug resistance mutations without crystal structures, applicable to oncology, antivirals, AMR). - Scientific/technical novelty: frontier approach (e.g., protein language model + drug fingerprints) that challenges existing paradigms. - Scalability and market need: clear path to commercialization (e.g., pharma partnerships, ARR roadmap). - Founder-program fit: alignment with EWOR's 'generational impact' thesis and willingness to engage in virtual mentorship/retreats. - Stage readiness: pre-seed, proof-of-concept validated, not yet incorporated (ideal for EWOR's early-stage focus).

EWOR does not publicly list named winners on the page, but past cohorts include founders from 35,000+ applicants (0.1% acceptance) building in deep tech, biotech, AI, and climate. Archetypes: solo founders with deep technical expertise, often from underrepresented regions (e.g., Africa, Eastern Europe), tackling global challenges with novel science. Examples from broader knowledge: founders like those in computational biology, AI-driven drug discovery, and hardware biotech.

A solo founder with a rare combination of deep domain expertise (e.g., pharmacy + ML engineering) and a breakthrough technology that is both scientifically rigorous and commercially viable. The venture should target a massive, underserved market (e.g., drug resistance prediction) with a clear, capital-efficient path to validation and partnership.